新型格列酮类化合物ANY_2对HepG_2细胞糖代谢的影响

Effects of a novel thiazolidinedione ANY_2 on glycometabolism in HepG_2 cells

目的:体外实验研究新型格列酮类化合物ANY2对糖代谢的影响。方法:采用高浓度胰岛素持续作用肝癌细胞株(HepG2)24h建立胰岛素抵抗模型(IR-HepG2),并观察ANY2对细胞葡萄糖消耗(GC)、对细胞内糖原含量、糖异生及糖酵解作用的影响。结果:ANY2能显著增加IR-HepG2在高、中、低糖条件下的葡萄糖消耗,并呈明显的剂量依赖性;增加IR-HepG2细胞内糖原含量,但与模型组相比,仅在高浓度差异有统计学意义;减少IR-HepG2细胞以乳酸为底物的糖异生量;提高糖酵解作用中IR-HepG2细胞乳酸的生成和细胞内丙酮酸激酶(PK)活力。结论:ANY2可显著改善IR-HepG2细胞的糖代谢作用。

AIM： To investigate the effects of a novel thiazolidinedione ANY2 on glycometabolism in HepG2 cells. METHODS： HepG2 cells are exposed to high concentrations of insulin for 24 h to build the model of insulin-resistance （IR-HepG2）. The effects of ANY2, including glucose consumption （GC）, gluconeogenesis and glucolysis were tested in this model. RESULTS： ANY2 could dose-dependently enhance GC in IR-HepG2 cells at high, medium and low levels of glucose. Compared with Modle Group, ANY2 increased IR-HepG2 cells glycogen synthesis significantly only in high dose group. It inhibited gluconeogenesis from lactic acid, but increased the production of lactic acid and the activity of pymvate kinase （PK） in glucolysis. CONCLUSION： Compound ANY2 has remarkable effects on improving glycometabolism in IR-HepG2 cells.